Next Generation NK Cell Therapy Poised to Transition into Human Clinical Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using

CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) today announced that members of the company’s management team will be presenting at the following upcoming investor conferences: Cowen &amp; Company’s 37th Annual Healthcare Conference on Wednesday, March 8th , at 9:20am ET

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.
The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.